

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Selinexor with bortezomib and low-dose  
dexamethasone for relapsed or refractory multiple  
myeloma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No potential equality issues have been identified by stakeholders. However, the company noted that multiple myeloma is more common in men, older people ( $\geq 75$ years) and people of African and Caribbean family background.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The committee would consider the higher prevalence of the condition in these groups.
--

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Ross Dent

**Date:** 14/06/2023